Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.